BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37483610)

  • 1. β-catenin attenuation leads to up-regulation of activating NKG2D ligands and tumor regression in
    Zou M; Al-Yahya S; Al-Alwan M; BinEssa HA; Khabar KSA; Almohanna F; Assiri AM; Altaweel A; Qattan A; Meyer BF; Alzahrani AS; Shi Y
    Front Immunol; 2023; 14():1171816. PubMed ID: 37483610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAF
    Zou M; BinEssa HA; Al-Malki YH; Al-Yahya S; Al-Alwan M; Al-Jammaz I; Khabar KSA; Almohanna F; Assiri AM; Meyer BF; Alzahrani AS; Al-Mohanna FA; Shi Y
    Mol Cancer Ther; 2021 Sep; 20(9):1603-1613. PubMed ID: 34224366
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic potential of Dickkopf-1 in wild-type BRAF papillary thyroid cancer via regulation of β-catenin/E-cadherin signaling.
    Cho SW; Kim YA; Sun HJ; Ahn HY; Lee EK; Yi KH; Oh BC; Park DJ; Cho BY; Park YJ
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1641-9. PubMed ID: 24848709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
    Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; Binessa HA; Alzahrani AS; Al-Khalaf HH; Hawwari A; Akhtar M; Assiri AM; Meyer BF; Shi Y
    Oncogene; 2016 Apr; 35(15):1909-18. PubMed ID: 26477313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
    Wang N; Wen J; Ren W; Wu Y; Deng C
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Zou M; Baitei EY; BinEssa HA; Al-Mohanna FA; Parhar RS; St-Arnaud R; Kimura S; Pritchard C; Alzahrani AS; Assiri AM; Meyer BF; Shi Y
    Cancer Res; 2017 Apr; 77(8):2161-2172. PubMed ID: 28242615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway.
    Ma J; Huang X; Li Z; Shen Y; Lai J; Su Q; Zhao J; Xu J
    J Cell Physiol; 2019 Aug; 234(10):17739-17748. PubMed ID: 30793770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAF
    Zhang P; Guan L; Sun W; Zhang Y; Du Y; Yuan S; Cao X; Yu Z; Jia Q; Zheng X; Meng Z; Li X; Zhao L
    Clin Transl Med; 2024 May; 14(5):e1694. PubMed ID: 38797942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/β-catenin signaling.
    Zhang X; Li M; Zuo K; Li D; Ye M; Ding L; Cai H; Fu D; Fan Y; Lv Z
    J Clin Endocrinol Metab; 2013 Aug; 98(8):E1305-13. PubMed ID: 23796566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in
    Valvo V; Iesato A; Kavanagh TR; Priolo C; Zsengeller Z; Pontecorvi A; Stillman IE; Burke SD; Liu X; Nucera C
    Thyroid; 2021 Sep; 31(9):1335-1358. PubMed ID: 33107403
    [No Abstract]   [Full Text] [Related]  

  • 11. Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/β-catenin signaling pathway.
    Zhou Z; Liu Y; Ma M; Chang L
    Biomed Pharmacother; 2017 Dec; 96():98-103. PubMed ID: 28965013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
    Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
    Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Diagnosis of High-Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAF
    Xie F; Yan L; Li YM; Lan Y; Xiao J; Zhang MB; Jin Z; Zhang Y; Tian XQ; Zhu YQ; Li ZP; Luo YK
    J Ultrasound Med; 2022 Nov; 41(11):2789-2802. PubMed ID: 35229905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma.
    Chen X; Lin S; Lin Y; Wu S; Zhuo M; Zhang A; Zheng J; You Z
    J Transl Med; 2022 Feb; 20(1):79. PubMed ID: 35123502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-12 immunotherapy of Braf(V600E)-induced papillary thyroid cancer in a mouse model.
    Parhar RS; Zou M; Al-Mohanna FA; Baitei EY; Assiri AM; Meyer BF; Shi Y
    Lab Invest; 2016 Jan; 96(1):89-97. PubMed ID: 26501867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
    Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation.
    Cho NL; Lin CI; Whang EE; Carothers AM; Moore FD; Ruan DT
    Thyroid; 2010 Jun; 20(6):615-22. PubMed ID: 20470206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOX18 exerts tumor-suppressive functions in papillary thyroid carcinoma through inhibition of Wnt/β-catenin signaling.
    Geng Q; Deng H; Fu J; Cui F
    Exp Cell Res; 2020 Nov; 396(1):112249. PubMed ID: 32858034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma.
    Al-Abdallah A; Jahanbani I; Mehdawi H; Ali RH; Al-Brahim N; Mojiminiyi O; Junaid TA
    Exp Mol Pathol; 2020 Apr; 113():104379. PubMed ID: 31935378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.